Ausgabe 9/2008
Inhalt (15 Artikel)
Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain
Robert M. Prins, Chengyi J. Shu, Caius G. Radu, Dan D. Vo, Haumith Khan-Farooqi, Horacio Soto, Meng-Yin Yang, Muh-Shi Lin, Stephanie Shelly, Owen N. Witte, Antoni Ribas, Linda M. Liau
Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses
Stephan Roux, Claire Bernat, Bassim Al-Sakere, François Ghiringhelli, Paule Opolon, Antoine F. Carpentier, Laurence Zitvogel, Lluis M. Mir, Caroline Robert
Development of a Listeria monocytogenes based vaccine against prostate cancer
Vafa Shahabi, Mariela Reyes-Reyes, Anu Wallecha, Sandra Rivera, Yvonne Paterson, Paulo Maciag
Impact of IFNα2b upon pSTAT3 and the MEK/ERK MAPK Pathway in Melanoma
Wenjun Wang, Howard D. Edington, Drazen M. Jukic, Uma N. M. Rao, Stephanie R. Land, John M. Kirkwood
Experimental manipulations of afferent immune responses influence efferent immune responses to brain tumors
Diana L. Thomas, David M. Kranz, Edward J. Roy
High frequency of immature dendritic cells and altered in situ production of interleukin-4 and tumor necrosis factor-α in lung cancer
R. B. Baleeiro, L. B. Anselmo, F. A. Soares, C. A. L. Pinto, O. Ramos, J. L. Gross, F. Haddad, R. N. Younes, M. Y. Tomiyoshi, P. C. Bergami-Santos, J. A. M. Barbuto
Investigation of the mechanisms of tissue factor-mediated evasion of tumour cells from cellular cytotoxicity
Chao Li, Mary E. W. Collier, G. Alkisitis Frentzou, John Greenman, Camille Ettelaie
Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer
Stephanie S. Tseng-Rogenski, Mohamed S. Arredouani, Yilin C. Neeley, Bin Lu, Arul M. Chinnaiyan, Martin G. Sanda
The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression
Michele C. Madigan, Elizabeth A. Kingsley, Paul J. Cozzi, Warick J. Delprado, Pamela J. Russell, Yong Li
CD54 is a surrogate marker of antigen presenting cell activation
N. A. Sheikh, L. A. Jones
Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design
Maciej Kmieciak, Johanna K. Morales, Joshua Morales, Elizabeth Bolesta, Margaret Grimes, Masoud H. Manjili
TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model
Hiroyuki Inoue, Mutsunori Iga, Meng Xin, Saori Asahi, Takafumi Nakamura, Ryo Kurita, Masaharu Nakayama, Yukoh Nakazaki, Koichi Takayama, Yoichi Nakanishi, Kenzaburo Tani
Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers
Antoun Toubaji, Moujahed Achtar, Maurizio Provenzano, Vincent E. Herrin, Robert Behrens, Michael Hamilton, Sarah Bernstein, David Venzon, Barry Gause, Francesco Marincola, Samir N. Khleif
Second international conference on cancer vaccines/adjuvants/delivery for the next decade (CVADD): Heidelberg, Germany, 10–12 October 2007
V. Schirrmacher, P. Beckhove, P. Fournier, V. Umansky